Business Context and Reporting Period
Company: Repligen Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended June 30, 2010
Business Overview: Repligen is a biopharmaceutical company focused on developing therapies for neurology, gastroenterology, and orphan diseases, alongside a commercial bioprocessing business. The company also generates significant royalty revenue from a settlement with Bristol-Myers Squibb regarding the drug Orencia.
Key Financial Metrics
| Metric | Q2 2010 | Q2 2009 |
|---|---|---|
| Total Revenue | $7,009,872 | $5,060,853 |
| Net Income (Loss) | $988,053 | $(1,105,980) |
| Earnings Per Share (Diluted) | $0.03 | $(0.04) |
| Operating Cash Flow | $(461,355) | $(1,867,626) |
| Cash and Cash Equivalents | $8,332,988 | $3,670,604 |
| Total Marketable Securities | $50,304,901 | $46,620,407 |
| Total Assets | $71,560,691 | $71,419,963 |
| Total Liabilities | $4,172,628 | $5,299,587 |
Margins: Gross margin on product revenue was approximately 70.4% ($4.27M revenue vs. $1.27M cost). Operating margin for the quarter was approximately 12.7% ($0.89M operating income vs. $7.01M revenue).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 39% year-over-year to $7.01 million. Product revenue surged 73% to $4.27 million, driven by increased orders from the largest customer. Royalty revenue increased 6% to $2.74 million, primarily due to higher sales of Orencia by Bristol-Myers Squibb.
- Profitability Turnaround: The company reported a net income of $0.99 million, a significant improvement from a net loss of $1.11 million in the prior year. This was driven by higher revenues and reduced operating expenses.
- Expense Reduction: Total operating expenses decreased 6% to $6.12 million. Research and development (R&D) expenses dropped 20% to $2.70 million, largely due to the conclusion of a Phase 3 clinical trial for RG1068. Selling, general, and administrative (SG&A) expenses increased 18% to $1.79 million due to healthcare costs and business development activities.
- Liquidity: While cash and cash equivalents decreased by $4.19 million during the quarter due to investing activities, total liquid assets (cash plus marketable securities) remained robust at approximately $58.6 million.
Guidance, Outlook, and Risks
Management Commentary: Management expects quarterly fluctuations in product revenue due to the timing of large-scale production orders and regulatory approvals for monoclonal antibodies. The company does not believe these fluctuations are necessarily predictive of future trends. R&D spending is expected to fluctuate based on the nature and timing of development activities.
Outlook: The company believes current cash and investment balances are adequate to meet needs for the foreseeable future, absent acquisitions. Future capital requirements depend on clinical study success, R&D progress, and royalty revenues.
Risks and Contingencies:
- Concentration Risk: Royalty revenue from Bristol-Myers Squibb represented 35% of total revenue. The largest bioprocessing customer accounted for 43% of total revenue.
- Development Risk: The company cannot reliably estimate when therapeutic product candidates will generate revenue. Significant risks exist regarding clinical trial success and regulatory approvals.
- Market Risk: A hypothetical 100 basis point increase in interest rates would result in an approximate $223,000 decrease in the fair value of investments.
- Intellectual Property: Risks include litigation regarding patent rights and the ability to maintain IP protection.
Key Facts for Investor Verification
- Revenue Concentration: Verify the stability of the top bioprocessing customer (43% of revenue) and the Bristol-Myers Squibb royalty stream (35% of revenue), as these two sources drive the majority of financial performance.
- Cash Burn vs. Income: Note the discrepancy between reported net income ($0.99M) and negative operating cash flow ($0.46M), driven by a $0.97M increase in accounts receivable and a $0.84M decrease in accrued liabilities.
- R&D Pipeline Status: Confirm the status of the RG1068 trial (concluded) and the new milestone payment to McLean Hospital regarding uridine for bipolar disorder, which impacted R&D expenses.
- Investment Portfolio: Review the composition of marketable securities ($50.3M), which are held-to-maturity, to assess liquidity flexibility versus interest rate risk.
- Future Obligations: Note the $6.14 million in total contractual obligations, including operating leases and purchase obligations for raw materials and clinical trials.